Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
- PMID: 36225629
- PMCID: PMC9548004
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
Abstract
Liposomal irinotecan plus 5-fluorouracil and leucovorin (nal-IRI + 5-FU/LV) treatment has demonstrated survival benefits but noticeable side effects in patients with pancreatic ductal adenocarcinoma (PDAC) that is refractory to gemcitabine-based therapy. This study aimed to explore whether combining albumin with the neutrophil-to-lymphocyte ratio (NLR), herein known as the albumin and neutrophil-to-lymphocyte ratio score (ANS), could be utilized as a simple tool to predict survival and safety profiles in such patient groups. We retrospectively enrolled 434 consecutive PDAC patients treated with nal-IRI + 5-FU/LV between 2018 and 2020 at nine medical centers in Taiwan. Patients were divided into three groups: ANS 0 (high albumin and low NLR), ANS 1 (low albumin or high NLR), and ANS 2 (low albumin and high NLR), for comparison. The median overall survival times for the ANS 0, 1, and 2 groups were 8.7 months (95% confidence interval (CI), 7.0-10.3 months), 5.2 months (95% CI, 4.3-6.0 months), and 2.6 months (95% CI, 1.9-3.3 months), respectively. The ANS was found to be an independent variable for overall survival and time-to-treatment failure in multivariate analyses. Patients in the ANS 2 group had significantly higher incidences of grade 3 or higher treatment-related adverse events than those in the other two groups. The present study showed that the ANS was an independent prognosticator in PDAC patients receiving nal-IRI + 5-FU/LV therapy. The ANS can be a simple predictor of survival outcome and safety profiles in PDAC patients treated with nal-IRI + 5-FU/LV.
Keywords: Albumin; liposomal irinotecan; neutrophil-to-lymphocyte ratio; pancreatic cancer; prognosis.
AJCR Copyright © 2022.
Conflict of interest statement
Author Sz-Chi Chiu was employed by the company PharmaEngine, Inc. The remaining authors declare that there is no conflict of interest.
Figures




Similar articles
-
Validation of a Prognostic Nomogram for Patients with Metastatic Pancreatic Cancer Treated with Nanoliposomal Irinotecan as Second-Line Therapy.Cancer Control. 2025 Jan-Dec;32:10732748251333040. doi: 10.1177/10732748251333040. Epub 2025 Apr 11. Cancer Control. 2025. PMID: 40216411 Free PMC article.
-
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study.Ther Adv Med Oncol. 2021 Nov 20;13:17588359211058255. doi: 10.1177/17588359211058255. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34819998 Free PMC article.
-
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.Eur J Cancer. 2019 Feb;108:78-87. doi: 10.1016/j.ejca.2018.12.007. Epub 2019 Jan 14. Eur J Cancer. 2019. PMID: 30654298 Clinical Trial.
-
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.Expert Opin Pharmacother. 2016 Jul;17(10):1413-20. doi: 10.1080/14656566.2016.1183646. Epub 2016 May 17. Expert Opin Pharmacother. 2016. PMID: 27140876 Review.
-
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.Drugs. 2020 Jul;80(10):1007-1018. doi: 10.1007/s40265-020-01336-6. Drugs. 2020. PMID: 32557396 Free PMC article. Review.
Cited by
-
Insight from Lymphocyte-Albumin Scores into Treatment Continuity of Nanoliposomal Irinotecan With 5-Fluorouracil and L-leucovorin in Metastatic Pancreatic Cancer.In Vivo. 2024 Nov-Dec;38(6):2873-2879. doi: 10.21873/invivo.13768. In Vivo. 2024. PMID: 39477393 Free PMC article.
-
Combined Serum ALBUMIN with Neutrophil-to-Lymphocyte Ratio Predicts the Prognosis of Biliary Tract Cancer after Curative Resection.Cancers (Basel). 2023 Nov 19;15(22):5474. doi: 10.3390/cancers15225474. Cancers (Basel). 2023. PMID: 38001734 Free PMC article.
-
Prognostic value of geriatric nutritional risk index for patients with biliary tract cancer undergoing surgical resection - a single-institution retrospective cohort study.Contemp Oncol (Pozn). 2023;27(2):65-70. doi: 10.5114/wo.2023.127436. Epub 2023 May 22. Contemp Oncol (Pozn). 2023. PMID: 37794990 Free PMC article.
-
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation.Biomed J. 2024 Jun;47(3):100696. doi: 10.1016/j.bj.2023.100696. Epub 2023 Dec 31. Biomed J. 2024. PMID: 38169173 Free PMC article. Review.
-
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis.Immunotherapy. 2025 Mar;17(4):269-281. doi: 10.1080/1750743X.2025.2483656. Epub 2025 Mar 25. Immunotherapy. 2025. PMID: 40134096 Review.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
-
- Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997;15:2403–2413. - PubMed
-
- Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703. - PMC - PubMed
-
- Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–557. - PubMed
LinkOut - more resources
Full Text Sources